Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aeruginosin 98-B is a bioactive small molecule natural product belonging to the aeruginosin family of oligopeptides produced by cyanobacteria such as Microcystis aeruginosa. It is characterized structurally as a dipeptide with unique moieties including Choi and guanidinobutyl groups. Aeruginosins are notable for their potent inhibition of serine proteases—particularly trypsin and thrombin—by binding to their active sites. Aeruginosin 98-B has demonstrated antitumor[3], anti-inflammatory[3], and antimicrobial activities[3]. Its absolute configuration was determined by X-ray crystallography in complex with thrombin and hirudin[8]. The compound is considered experimental; it has not been approved for clinical use or entered advanced clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aeruginosin 98-b.